Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAAVIGATE: Surabgene Lomparvovec in Diabetic Retinopathy
NCT07592273Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 2
01
Overview
A Phase 3 trial of surabgene lomparvovec in diabetic retinopathy (DR), sponsored by AbbVie Inc.. Started Jun 2026; status: recruiting.
02
Drugs
surabgene lomparvovec
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT07592273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07592273.